>>Signaling Pathways>> Angiogenesis>>Sucrose octasulfate (potassium salt)

Sucrose octasulfate (potassium salt) (Synonyms: SOS, Sucrosofate potassium)

Catalog No.GC44966

Sucrose octasulfate (SOS), a component of the gastrointestinal protectant sucralfate, is an alkaline aluminum-sucrose complex that inhibits peptic hydrolysis and raises gastric pH, protecting esophageal epithelium against acid injury.

Products are for research use only. Not for human use. We do not sell to patients.

Sucrose octasulfate (potassium salt) Chemical Structure

Cas No.: 73264-44-5

Size 가격 재고 수량
500mg
US$121.00
재고 있음
1g
US$168.00
재고 있음
5g
US$780.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Sucrose octasulfate (SOS), a component of the gastrointestinal protectant sucralfate, is an alkaline aluminum-sucrose complex that inhibits peptic hydrolysis and raises gastric pH, protecting esophageal epithelium against acid injury. It can bind to exosite II of thrombin (KD = ~1.4 µM) and inhibit its catalytic activity (IC50 = 4.5 µM) and, as such, has been used as a surrogate for heparin. Furthermore, SOS has been shown to inhibit tumor growth in mouse melanoma and lung carcinoma models by preventing fibroblast growth factor 2 (FGF-2) binding to endothelial cells and also by removing any pre-bound FGF-2 from these cells (IC50 = ~2 µg/ml).

리뷰

Review for Sucrose octasulfate (potassium salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 15 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Sucrose octasulfate (potassium salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.